Fig. 6.

BDNF inhibited microglial activation via upregulation of Erk-CREB signaling. a, b Representative immunofluorescent images show the distribution of p-CREB and p-p65 in the BV-2 cells. Scale bar, 10 μm. c Interaction of CBP with p-CREB and p-p65, assessed by immunoprecipitation of CBP followed by immunoblot for p-CREB and p-p65. d, e Levels of p-Erk (n = 4) and p-CREB (n = 4) in the BV2 cells. f Levels of TNF (n = 4) and IL-6 (n = 4) in conditioned media. *p < 0.05, **p < 0.01, ***p < 0.001 versus LPS(-)BDNF(-)PD98059(-) group; ^#p < 0.05, , ^###p < 0.001 versus LPS(+)BDNF(-)PD98059(-) group; ^$P < 0.05, ^$$P < 0.01 versus LPS(+)BDNF(+)PD98059(-) group. g–i Levels of p-Akt (n = 4), p-GSK3-β (n = 4) and MKP-1 (n = 4) in the BV2 cells. *p < 0.05, **p < 0.01, ***p < 0.001 versus LPS(-)BDNF(-) group; ^#p < 0.05 versus LPS(+)BDNF(-) group. Data are presented as mean ± S.D